Skip to main content
Top
Published in: Respiratory Research 1/2012

Open Access 01-12-2012 | Research

"GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study"

Authors: Gülmisal Güder, Susanne Brenner, Christiane E Angermann, Georg Ertl, Matthias Held, Alfred P Sachs, Jan-Willem Lammers, Pieter Zanen, Arno W Hoes, Stefan Störk, Frans H Rutten

Published in: Respiratory Research | Issue 1/2012

Login to get access

Abstract

Background

The Global initiative for chronic Obstructive Lung Disease (GOLD) defines COPD as a fixed post-bronchodilator ratio of forced expiratory volume in 1 second and forced vital capacity (FEV1/FVC) below 0.7. Age-dependent cut-off values below the lower fifth percentile (LLN) of this ratio derived from the general population have been proposed as an alternative. We wanted to assess the diagnostic accuracy and prognostic capability of the GOLD and LLN definition when compared to an expert-based diagnosis.

Methods

In a prospective cohort study, 405 patients aged ≥ 65 years with a general practitioner's diagnosis of COPD were recruited and followed up for 4.5 (median; quartiles 3.9; 5.1) years. Prevalence rates of COPD according to GOLD and three LLN definitions and diagnostic performance measurements were calculated. The reference standard was the diagnosis of COPD of an expert panel that used all available diagnostic information, including spirometry and bodyplethysmography.

Results

Compared to the expert panel diagnosis, 'GOLD-COPD' misclassified 69 (28%) patients, and the three LLNs misclassified 114 (46%), 96 (39%), and 98 (40%) patients, respectively. The GOLD classification led to more false positives, the LLNs to more false negative diagnoses. The main predictors beyond the FEV1/FVC ratio for an expert diagnosis of COPD were the FEV1 % predicted, and the residual volume/total lung capacity ratio (RV/TLC). Adding FEV1 and RV/TLC to GOLD or LLN improved the diagnostic accuracy, resulting in a significant reduction of up to 50% of the number of misdiagnoses. The expert diagnosis of COPD better predicts exacerbations, hospitalizations and mortality than GOLD or LLN.

Conclusions

GOLD criteria over-diagnose COPD, while LLN definitions under-diagnose COPD in elderly patients as compared to an expert panel diagnosis. Incorporating FEV1 and RV/TLC into the GOLD-COPD or LLN-based definition brings both definitions closer to expert panel diagnosis of COPD, and to daily clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997, 349 (9064): 1498-1504. 10.1016/S0140-6736(96)07492-2.PubMedCrossRef Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997, 349 (9064): 1498-1504. 10.1016/S0140-6736(96)07492-2.PubMedCrossRef
2.
go back to reference Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M: Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm. 2008, 14 (2): 176-185.PubMed Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M: Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm. 2008, 14 (2): 176-185.PubMed
3.
go back to reference Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23 (6): 932-946. 10.1183/09031936.04.00014304.PubMedCrossRef Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23 (6): 932-946. 10.1183/09031936.04.00014304.PubMedCrossRef
4.
go back to reference Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176 (6): 532-555. 10.1164/rccm.200703-456SO.PubMedCrossRef Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176 (6): 532-555. 10.1164/rccm.200703-456SO.PubMedCrossRef
5.
go back to reference Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, Stocks J, Quanjer PH: Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008, 63 (12): 1046-1051. 10.1136/thx.2008.098483.PubMedCrossRef Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, Stocks J, Quanjer PH: Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008, 63 (12): 1046-1051. 10.1136/thx.2008.098483.PubMedCrossRef
6.
go back to reference Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001, 163 (5): 1256-1276.PubMedCrossRef Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001, 163 (5): 1256-1276.PubMedCrossRef
7.
go back to reference Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O: Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002, 20 (5): 1117-1122. 10.1183/09031936.02.00023202.PubMedCrossRef Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O: Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002, 20 (5): 1117-1122. 10.1183/09031936.02.00023202.PubMedCrossRef
8.
go back to reference Celli BR, Halbert RJ, Isonaka S, Schau B: Population impact of different definitions of airway obstruction. Eur Respir J. 2003, 22 (2): 268-273. 10.1183/09031936.03.00075102.PubMedCrossRef Celli BR, Halbert RJ, Isonaka S, Schau B: Population impact of different definitions of airway obstruction. Eur Respir J. 2003, 22 (2): 268-273. 10.1183/09031936.03.00075102.PubMedCrossRef
9.
go back to reference Hansen JE, Sun XG, Wasserman K: Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest. 2007, 131 (2): 349-355. 10.1378/chest.06-1349.PubMedCrossRef Hansen JE, Sun XG, Wasserman K: Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest. 2007, 131 (2): 349-355. 10.1378/chest.06-1349.PubMedCrossRef
10.
go back to reference Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26 (5): 948-968. 10.1183/09031936.05.00035205.PubMedCrossRef Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26 (5): 948-968. 10.1183/09031936.05.00035205.PubMedCrossRef
11.
go back to reference Moons KG, Grobbee DE: When should we remain blind and when should our eyes remain open in diagnostic studies?. J Clin Epidemiol. 2002, 55 (7): 633-636. 10.1016/S0895-4356(02)00408-0.PubMedCrossRef Moons KG, Grobbee DE: When should we remain blind and when should our eyes remain open in diagnostic studies?. J Clin Epidemiol. 2002, 55 (7): 633-636. 10.1016/S0895-4356(02)00408-0.PubMedCrossRef
12.
go back to reference Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW: Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005, 26 (18): 1887-1894. 10.1093/eurheartj/ehi291.PubMedCrossRef Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW: Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005, 26 (18): 1887-1894. 10.1093/eurheartj/ehi291.PubMedCrossRef
13.
go back to reference Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW: The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009, 11 (12): 1182-1188. 10.1093/eurjhf/hfp148.PubMedCrossRef Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW: The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009, 11 (12): 1182-1188. 10.1093/eurjhf/hfp148.PubMedCrossRef
14.
go back to reference Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 5-40.PubMedCrossRef Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 5-40.PubMedCrossRef
15.
go back to reference The Pulmonaria Group CRO, Enright PL, Falaschetti E, Hankinson JL, Jenkins C, Jensen RL, Miller MR, Pedersen OF, Quanjer PH, Ruppel GL, Schouten JP, Stocks J, Swanney MP: Interpreting Spirometric Test Results. [http://www.spirxpert.com] The Pulmonaria Group CRO, Enright PL, Falaschetti E, Hankinson JL, Jenkins C, Jensen RL, Miller MR, Pedersen OF, Quanjer PH, Ruppel GL, Schouten JP, Stocks J, Swanney MP: Interpreting Spirometric Test Results. [http://​www.​spirxpert.​com]
16.
go back to reference Enright PL, Adams AB, Boyle PJ, Sherrill DL: Spirometry and maximal respiratory pressure references from healthy Minnesota 65- to 85-year-old women and men. Chest. 1995, 108 (3): 663-669. 10.1378/chest.108.3.663.PubMedCrossRef Enright PL, Adams AB, Boyle PJ, Sherrill DL: Spirometry and maximal respiratory pressure references from healthy Minnesota 65- to 85-year-old women and men. Chest. 1995, 108 (3): 663-669. 10.1378/chest.108.3.663.PubMedCrossRef
17.
go back to reference Falaschetti E, Laiho J, Primatesta P, Purdon S: Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J. 2004, 23 (3): 456-463. 10.1183/09031936.04.00055204.PubMedCrossRef Falaschetti E, Laiho J, Primatesta P, Purdon S: Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J. 2004, 23 (3): 456-463. 10.1183/09031936.04.00055204.PubMedCrossRef
18.
go back to reference Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33 (1): 159-174. 10.2307/2529310.PubMedCrossRef Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33 (1): 159-174. 10.2307/2529310.PubMedCrossRef
19.
go back to reference Vanbelle SAA: A bootstrap method for comparing correlated kappa coefficients. Journal of Statistical Computation & Simulation. 2008, 78: 1009-1015. 10.1080/00949650701410249.CrossRef Vanbelle SAA: A bootstrap method for comparing correlated kappa coefficients. Journal of Statistical Computation & Simulation. 2008, 78: 1009-1015. 10.1080/00949650701410249.CrossRef
20.
go back to reference Carpenter J, Bithell J: Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians". Statistics in Medicine. 2000, 19: 1141-1164. 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F.PubMedCrossRef Carpenter J, Bithell J: Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians". Statistics in Medicine. 2000, 19: 1141-1164. 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F.PubMedCrossRef
21.
go back to reference Greenland S, Finkle WD: A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995, 142 (12): 1255-1264.PubMed Greenland S, Finkle WD: A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995, 142 (12): 1255-1264.PubMed
22.
go back to reference Calverley PM: The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med. 2004, 170 (3): 211-212. 10.1164/rccm.2405008. discussion 214PubMedCrossRef Calverley PM: The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med. 2004, 170 (3): 211-212. 10.1164/rccm.2405008. discussion 214PubMedCrossRef
23.
go back to reference Bellia V, Sorino C, Catalano F, Augugliaro G, Scichilone N, Pistelli R, Pedone C, Antonelli-Incalzi R: Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax. 2008, 63 (1): 60-66. 10.1136/thx.2007.080572.PubMedCrossRef Bellia V, Sorino C, Catalano F, Augugliaro G, Scichilone N, Pistelli R, Pedone C, Antonelli-Incalzi R: Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax. 2008, 63 (1): 60-66. 10.1136/thx.2007.080572.PubMedCrossRef
24.
go back to reference Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG, Wood KL: FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest. 2006, 130 (1): 200-206. 10.1378/chest.130.1.200.PubMedCrossRef Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG, Wood KL: FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest. 2006, 130 (1): 200-206. 10.1378/chest.130.1.200.PubMedCrossRef
25.
go back to reference Schermer TR, Smeele IJ, Thoonen BP, Lucas AE, Grootens JG, van Boxem TJ, Heijdra YF, van Weel C: Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J. 2008, 32 (4): 945-952. 10.1183/09031936.00170307.PubMedCrossRef Schermer TR, Smeele IJ, Thoonen BP, Lucas AE, Grootens JG, van Boxem TJ, Heijdra YF, van Weel C: Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J. 2008, 32 (4): 945-952. 10.1183/09031936.00170307.PubMedCrossRef
26.
go back to reference Salpeter SR, Ormiston TM, Salpeter EE: Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004, 125 (6): 2309-2321. 10.1378/chest.125.6.2309.PubMedCrossRef Salpeter SR, Ormiston TM, Salpeter EE: Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004, 125 (6): 2309-2321. 10.1378/chest.125.6.2309.PubMedCrossRef
27.
go back to reference Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E: Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008, 300 (20): 2407-2416. 10.1001/jama.2008.717.PubMedCrossRef Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E: Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008, 300 (20): 2407-2416. 10.1001/jama.2008.717.PubMedCrossRef
28.
go back to reference Singh S, Loke YK, Furberg CD: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008, 300 (12): 1439-1450. 10.1001/jama.300.12.1439.PubMedCrossRef Singh S, Loke YK, Furberg CD: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008, 300 (12): 1439-1450. 10.1001/jama.300.12.1439.PubMedCrossRef
29.
go back to reference Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW: Heart failure and chronic obstructive pulmonary disease: An ignored combination?. Eur J Heart Fail. 2006, 8 (7): 706-711. 10.1016/j.ejheart.2006.01.010.PubMedCrossRef Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW: Heart failure and chronic obstructive pulmonary disease: An ignored combination?. Eur J Heart Fail. 2006, 8 (7): 706-711. 10.1016/j.ejheart.2006.01.010.PubMedCrossRef
30.
go back to reference Toljamo T, Kaukonen M, Nieminen P, Kinnula VL: Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care. 28 (1): 41-46. Toljamo T, Kaukonen M, Nieminen P, Kinnula VL: Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care. 28 (1): 41-46.
31.
go back to reference Dusser D, Bravo ML, Iacono P: The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006, 27 (3): 547-555. 10.1183/09031936.06.00062705.PubMedCrossRef Dusser D, Bravo ML, Iacono P: The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006, 27 (3): 547-555. 10.1183/09031936.06.00062705.PubMedCrossRef
32.
go back to reference Jones PW, Bosh TK: Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997, 155 (4): 1283-1289.PubMedCrossRef Jones PW, Bosh TK: Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997, 155 (4): 1283-1289.PubMedCrossRef
33.
go back to reference Dykstra BJ, Scanlon PD, Kester MM, Beck KC, Enright PL: Lung volumes in 4,774 patients with obstructive lung disease. Chest. 1999, 115 (1): 68-74. 10.1378/chest.115.1.68.PubMedCrossRef Dykstra BJ, Scanlon PD, Kester MM, Beck KC, Enright PL: Lung volumes in 4,774 patients with obstructive lung disease. Chest. 1999, 115 (1): 68-74. 10.1378/chest.115.1.68.PubMedCrossRef
34.
go back to reference National Collaborating Centre for Chronic Conditions. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004, 59 (Suppl (1)): 1-232. National Collaborating Centre for Chronic Conditions. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004, 59 (Suppl (1)): 1-232.
35.
go back to reference Worster A, Carpenter C: Incorporation bias in studies of diagnostic tests: how to avoid being biased about bias. CJEM. 2008, 10 (2): 174-175.PubMed Worster A, Carpenter C: Incorporation bias in studies of diagnostic tests: how to avoid being biased about bias. CJEM. 2008, 10 (2): 174-175.PubMed
Metadata
Title
"GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study"
Authors
Gülmisal Güder
Susanne Brenner
Christiane E Angermann
Georg Ertl
Matthias Held
Alfred P Sachs
Jan-Willem Lammers
Pieter Zanen
Arno W Hoes
Stefan Störk
Frans H Rutten
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2012
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-13-13

Other articles of this Issue 1/2012

Respiratory Research 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine